You have access to SA issues and articles on Sciam through institutional access. Click here if you'd like to opt out.

You have access to Scientific American issues and magazine articles through your institution’s site license

Skip to main content

Features

Party-Drug-Turned-Antidepressant Approaches Approval
Medicine

Party-Drug-Turned-Antidepressant Approaches Approval

Johnson & Johnson has submitted its esketamine for regulatory approval, but researchers still don't understand how the fast-acting antidepressant lifts moods

By Sara Reardon and Nature Reviews Drug Discovery
The Silent Epidemic Killing More People Than HIV, Malaria or TB
Public Health

The Silent Epidemic Killing More People Than HIV, Malaria or TB

Viral hepatitis is on the rise. Tackling hepatitis B in Africa is key to fighting back

By Ian Graber-Stiehl and Nature magazine
Model Citizens
Public Health

Model Citizens

How digital drug dealers and virtual users are providing clues to help stop the U.S. opioid epidemic

By Sara Reardon

Departments

  • What Do Americans Think about Food Additives and GMOs?

  • Has Your Health Insurance Really Got You Covered?

  • Why Doctors Reject Tools That Make Their Jobs Easier

  • Viruses on a Plane: What Emirates Flight EK203 Teaches Us

  • Addressing Cultural Bias in Medicine

  • From the Editor

    New Frontiers in Health and Medicine

  • News

    How Marijuana Use During Pregnancy Could Harm a Developing Baby's Brain

  • How Might the Appendix Play a Key Role in Parkinson's Disease?

  • A New Connection between the Gut and Brain

  • Too Good to Be True? A Nonaddictive Opioid without Lethal Side Effects Shows Promise

  • The Biology of Sugars Points to a Sweet Strategy for Treating Cancer

Purchase To Read More

Already purchased this issue? Sign In to Access
Select Format
Scroll To Top